Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company Drug

Eli Lilly’s Tirzepatide Earns China Approval for Type 2 Diabetes Treatment

Fineline Cube May 21, 2024

Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced that it...

Company Deals

Blue Sail Medical Subsidiary Secures RMB 100 Million Investment to Expand Operations

Fineline Cube May 21, 2024

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced that Blue Sail Biosensors Medical...

Company Deals

Jiayue Pharmaceutical’s JYP0015 Secures $365 Million Licensing Agreement with Erasca

Fineline Cube May 21, 2024

Guangzhou Jiayue Pharmaceutical Technology Co., Ltd, a Chinese pharmaceutical company, has entered into a licensing...

Policy / Regulatory

China’s CDE Reports Record High in Clinical Trials for Innovative Drugs in 2023

Fineline Cube May 21, 2024

The Center for Drug Evaluation (CDE) has released its annual report, highlighting the growth in...

Company Drug

Gilead’s Seladelpar Shows Interim Benefits in PBC-Related Itch Clinical Trial

Fineline Cube May 21, 2024

Gilead Sciences (NASDAQ: GILD) has announced interim results from a long-term study assessing the safety...

Company

AstraZeneca Commits $1.5 Billion to Build Singapore-Based ADC Manufacturing Facility

Fineline Cube May 21, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced plans for a $1.5 billion greenfield...

Policy / Regulatory

NHSA Unveils 2024 Medical Procurement Overhaul, Aiming for Synergy Between National and Provincial Levels

Fineline Cube May 21, 2024

The National Healthcare Security Administration (NHSA) has issued a notification detailing plans to enhance the...

Company Medical Device

BGI Genomics Delays Market Filing for BRCA1/2 Detection Kit Due to Incomplete Data

Fineline Cube May 21, 2024

BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced...

Company Medical Device

Hymson Laser’s Mid Infrared Femtosecond Laser Technology Makes Medical Industry Inroads

Fineline Cube May 21, 2024

Shenzhen-based Hymson Laser Technology Group Co., Ltd (SHA: 688559) has announced a significant breakthrough with...

Company Drug

BMS’s Sotyktu Sustains Clinical Response in Long-Term Psoriasis Treatment

Fineline Cube May 21, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has announced the release of long-term clinical data for...

Policy / Regulatory

China and South Korea Reinforce Ties with Renewed MOU on Pharmaceuticals and Cosmetics Regulation

Fineline Cube May 21, 2024

The National Medical Products Administration (NMPA) of China and the Ministry of Food and Drug...

Company Deals

Pharmaron and AstraZeneca Enter Sweeping Partnership to Span Drug Development Services

Fineline Cube May 21, 2024

Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759;...

Company Drug

Jiangsu Hengrui’s SHR1905 Anti-TSLP mAb Gets Green Light for COPD Clinical Trial

Fineline Cube May 21, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, announced that it...

Company Drug

Innovent Biologics’ IBI311 New Drug Application Accepted for Review by China’s CDE

Fineline Cube May 21, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...

Company Deals Digital Hospital

Union Hospital Teams Up with Baidu Health for AI-Enhanced Outpatient Services

Fineline Cube May 20, 2024

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, has entered into a...

Company Drug

Zai Lab and Innoviva Win China Approval for SUL-DUR to Treat Hospital-Acquired Pneumonia

Fineline Cube May 20, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, in collaboration with US...

Company Drug

FDA Gives Accelerated Nod to Amgen’s Imdelltra in Small Cell Lung Cancer

Fineline Cube May 20, 2024

The US Food and Drug Administration (FDA) has granted accelerated approval to Amgen (NASDAQ: AMGN)...

Company Drug

Eli Lilly’s Weekly Insulin Efsitora Alfa Matches Daily Basal Insulins in Reducing A1C Levels

Fineline Cube May 20, 2024

Eli Lilly and Company (NYSE: LLY), a global healthcare company, has announced results from a...

Company Deals

Pharmaron to Sell Proteologix Stake in Upcoming Johnson & Johnson Acquisition

Fineline Cube May 20, 2024

Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759;...

Company Deals

Fosun Pharma Nods to Fosun Health Spin-Off; IPO Venue and Requirements Under Review

Fineline Cube May 20, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in...

Posts pagination

1 … 365 366 367 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.